Blarcamesine HCl
Anavex2-73 is a muscarinic/σ1 ligand. ANAVEX2-73 (0.01-3.0 mg/kg i.p.) alleviated the scopolamine- and dizocilpine-induced learning impairments. ANAVEX2-73 (300 µg/kg) also reversed the learning deficits in mice injected with Aβ(25-35) peptide, a non-transgenic Alzheimer's disease model. The neuroprotective activity of ANAVEX2-73, its mixed cholinergic/σ(1) activity, its low active dose range and its long duration of action together reinforce its therapeutic potential in Alzheimer's disease.
仅供研究使用。 我们不向患者出售。
化学信息
| 名称 | Blarcamesine HCl |
|---|---|
| Iupac 化学名称 | 1-(2,2-diphenyltetrahydrofuran-3-yl)-N,N-dimethylmethanamine hydrochloride |
| 同义词 | Anavex-2-73; Anavex2-73; Anavex 2-73; Anavex-273; Anavex273; Anavex 273; AE-37 hydrochloride |
| 英文同义词 | Anavex-2-73; Anavex2-73; Anavex 2-73; Anavex-273; Anavex273; Anavex 273; AE-37 hydrochloride |
| 分子式 | C19H24ClNO |
| 分子量 | 317.85 |
| Smile | CN(C)CC1C(C2=CC=CC=C2)(C3=CC=CC=C3)OCC1.[H]Cl |
| InChiKey | FEQOLYDPQKHFTD-UHFFFAOYSA-N |
| InChi | InChI=1S/C19H23NO.ClH/c1-20(2)15-18-13-14-21-19(18,16-9-5-3-6-10-16)17-11-7-4-8-12-17;/h3-12,18H,13-15H2,1-2H3;1H |
| Cas号 | 195615-84-0 |
| 相关CAS号 |
订购信息
| 包装 | 价格 | 库存 | 纯度 | 备货期 |
|---|---|---|---|---|
| 大货 | 询价 | 询价 | 询价 |
| 外观性状 | 固体粉末 |
|---|---|
| 纯度 | 98% Min. |
| 存储 | 短期（几天到几周）为0-4摄氏度，长期（几个月）为-20摄氏度 |
| 可溶性 | 溶于DMSO |
| 处理方式 | |
| 运输条件 | 作为非危险化学品在环境温度下装运。这种产品在正常运输和海关工作期间可以稳定几周. |
| 海关编码 |
| Targets | |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |
1: Goguadze N, Zhuravliova E, Morin D, Mikeladze D, Maurice T. Sigma-1 Receptor Agonists Induce Oxidative Stress in Mitochondria and Enhance Complex I Activity in Physiological Condition but Protect Against Pathological Oxidative Stress. Neurotox Res. 2017 Nov 10. doi: 10.1007/s12640-017-9838-2. [Epub ahead of print] PubMed PMID: 29127580.
2: Maurice T. Protection by sigma-1 receptor agonists is synergic with donepezil, but not with memantine, in a mouse model of amyloid-induced memory impairments. Behav Brain Res. 2016 Jan 1;296:270-278. doi: 10.1016/j.bbr.2015.09.020. Epub 2015 Sep 16. PubMed PMID: 26386305.
3: Mason VL. Alzheimer's Association International Conference on Alzheimer's Disease 2015 (AAIC 2015) (July 18-23, 2015 - Washington, D.C., USA). Drugs Today (Barc). 2015 Jul;51(7):447-52. doi: 10.1358/dot.2015.51.7.2375989. PubMed PMID: 26261847.
4: Lahmy V, Long R, Morin D, Villard V, Maurice T. Mitochondrial protection by the mixed muscarinic/σ1 ligand ANAVEX2-73, a tetrahydrofuran derivative, in Aβ25-35 peptide-injected mice, a nontransgenic Alzheimer's disease model. Front Cell Neurosci. 2015 Jan 20;8:463. doi: 10.3389/fncel.2014.00463. eCollection 2014. PubMed PMID: 25653589; PubMed Central PMCID: PMC4299448.
5: Lahmy V, Meunier J, Malmström S, Naert G, Givalois L, Kim SH, Villard V, Vamvakides A, Maurice T. Blockade of Tau hyperphosphorylation and Aβ₁₋₄₂ generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and σ₁ receptor agonist, in a nontransgenic mouse model of Alzheimer's disease. Neuropsychopharmacology. 2013 Aug;38(9):1706-23. doi: 10.1038/npp.2013.70. Epub 2013 Mar 14. PubMed PMID: 23493042; PubMed Central PMCID: PMC3717544.
6: Villard V, Espallergues J, Keller E, Vamvakides A, Maurice T. Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma 1 (σ1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative. J Psychopharmacol. 2011 Aug;25(8):1101-17. doi: 10.1177/0269881110379286. Epub 2010 Sep 9. PubMed PMID: 20829307.
